

い) では, 甲状腺被曝線量との関連性は現在認められていない。

E. 引用文献

1. Gal RL, Gal TJ, Klotch DW, Cantor AB. Risk factors associated with hypothyroidism after laryngectomy. *Otolaryngol Head Neck Surg.* Sep 2000;123(3):211-217.
2. Alterio D, Jereczek-Fossa BA, Franchi B, et al. Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: A retrospective analysis of seventy-three patients. *Int J Radiat Oncol Biol Phys.* Jan 1 2007;67(1):144-150.
3. Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. *Arch Otolaryngol Head Neck Surg.* Oct 2006;132(10):1041-1046.
4. Norris AA, Amdur RJ, Morris CG, Mendenhall WM. Hypothyroidism when the thyroid is included only in the low neck field during head and neck radiotherapy. *Am J Clin Oncol.* Oct 2006;29(5):442-445.
5. Garcia-Serra A, Amdur RJ, Morris CG, Mazzaferri E, Mendenhall WM. Thyroid function should be monitored following radiotherapy to the low neck. *Am J Clin Oncol.* Jun 2005;28(3):255-258.
6. Tell R, Lundell G, Nilsson B, Sjodin H, Lewin F, Lewensohn R. Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. *Int J Radiat Oncol Biol Phys.* Oct 1 2004;60(2):395-400.
7. Yoden E, Soejima T, Maruta T, et al. [Hypothyroidism after radiotherapy to the neck]. *Nippon Igaku Hoshasen Gakkai Zasshi.* Mar 2004;64(3):146-150.
8. van Santen HM, Vulsma T, Dijkgraaf MG, et al. No damaging effect of chemotherapy in addition to radiotherapy on the thyroid axis in young adult survivors of childhood cancer. *J Clin Endocrinol Metab.* Aug 2003;88(8):3657-3663.
9. Abitbol A, Abdel-Wahab M, Lewin A, et al. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. *Int J Radiat Oncol Biol Phys.* Jul 15 2002;53(4):942-947.
10. Mercado G, Adelstein DJ, Saxton JP, Secic M, Larto MA, Lavertu P. Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. *Cancer.* Dec 1 2001;92(11):2892-2897.
11. Paulino AC, Simon JH, Zhen W, Wen BC. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. *Int J Radiat Oncol Biol Phys.* Dec 1 2000;48(5):1489-1495.

12. Zubizarreta PA, D'Antonio G, Raslawski E, et al. Nasopharyngeal carcinoma in childhood and adolescence: a single-institution experience with combined therapy. *Cancer*. Aug 1 2000;89(3):690-695.
13. Smolarz K, Malke G, Voth E, et al. Hypothyroidism after therapy for larynx and pharynx carcinoma. *Thyroid*. May 2000;10(5):425-429.
14. Crom DB, Kaste SC, Tubergen DG, Greenwald CA, Sharp GB, Hudson MM. Ultrasonography for thyroid screening after head and neck irradiation in childhood cancer survivors. *Med Pediatr Oncol*. Jan 1997;28(1):15-21.
15. Kumpulainen EJ, Hirvikoski PP, Virtaniemi JA, et al. Hypothyroidism after radiotherapy for laryngeal cancer. *Radiother Oncol*. Oct 2000;57(1):97-101.
16. Sinard RJ, Tobin EJ, Mazzaferri EL, et al. Hypothyroidism after treatment for nonthyroid head and neck cancer. *Arch Otolaryngol Head Neck Surg*. May 2000;126(5):652-657.
17. Tell R, Sjodin H, Lundell G, Lewin F, Lewensohn R. Hypothyroidism after external radiotherapy for head and neck cancer. *Int J Radiat Oncol Biol Phys*. Sep 1 1997;39(2):303-308.
18. Bethge W, Guggenberger D, Bamberg M, Kanz L, Bokemeyer C. Thyroid toxicity of treatment for Hodgkin's disease. *Ann Hematol*. Mar 2000;79(3):114-118.
19. Metzger ML, Hudson MM, Somes GW, et al. White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin's lymphoma. *J Clin Oncol*. Apr 1 2006;24(10):1516-1521.
20. Chow LM, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. *J Clin Oncol*. Dec 20 2006;24(36):5735-5741.
21. Illes A, Biro E, Miltenyi Z, et al. Hypothyroidism and thyroiditis after therapy for Hodgkin's disease. *Acta Haematol*. 2003;109(1):11-17.
22. Liao Z, Ha CS, Vlachaki MT, et al. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. *Int J Radiat Oncol Biol Phys*. Jul 15 2001;50(4):971-977.
23. Enrici RM, Anselmo AP, Donato V, et al. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD. *Haematologica*. Oct 1999;84(10):917-923.
24. Sears JD, Greven KM, Ferree CR, D'Agostino RB, Jr. Definitive irradiation in the treatment of Hodgkin's disease. Analysis of outcome, prognostic factors, and long-term complications. *Cancer*. Jan 1 1997;79(1):145-151.
25. Solt I, Gaitini D, Pery M, Hochberg Z, Stein M, Arush MW. Comparing thyroid ultrasonography to thyroid function in long-term survivors of childhood lymphoma. *Med Pediatr*

- Oncol*. Jul 2000;35(1):35-40.
26. Shafford EA, Kingston JE, Healy JC, Webb JA, Plowman PN, Reznek RH. Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin's disease. *Br J Cancer*. May 1999;80(5-6):808-814.
 27. Atahan IL, Yildiz F, Ozyar E, Uzal D. Thyroid dysfunction in children receiving neck irradiation for Hodgkin's disease. *Radiat Med*. Sep-Oct 1998;16(5):359-361.
 28. Khoo VS, Liew KH, Crennan EC, D'Costa IM, Quong G. Thyroid dysfunction after mantle irradiation of Hodgkin's disease patients. *Australas Radiol*. Feb 1998;42(1):52-57.
 29. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. *N Engl J Med*. Aug 29 1991;325(9):599-605.
 30. Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. *J Clin Endocrinol Metab*. Dec 1999;84(12):4472-4479.
 31. Bhansali A, Banerjee AK, Chanda A, et al. Radiation-induced brain disorders in patients with pituitary tumours. *Australas Radiol*. Sep 2004;48(3):339-346.
 32. Spoudeas HA, Charmandari E, Brook CG. Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. *Med Pediatr Oncol*. Apr 2003;40(4):224-229.
 33. Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Poulsen HS, Muller J. A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor. *J Clin Endocrinol Metab*. Jan 2003;88(1):136-140.
 34. Paulino AC. Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy. *Int J Radiat Oncol Biol Phys*. Jul 1 2002;53(3):543-547.
 35. Ricardi U, Corrias A, Einaudi S, et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. *Int J Radiat Oncol Biol Phys*. Aug 1 2001;50(5):1287-1294.
 36. Pai HH, Thornton A, Katznelson L, et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. *Int J Radiat Oncol Biol Phys*. Mar 15 2001;49(4):1079-1092.
 37. Todd A, Ruge J. Medulloblastoma - late outcome. *Crit Rev Neurosurg*. May 25 1999;9(3):174-179.
 38. Arlt W, Hove U, Muller B, et al. Frequent and frequently overlooked: treatment-induced endocrine dysfunction in adult long-term survivors of primary brain tumors. *Neurology*. Aug 1997;49(2):498-506.

39. Chin D, Sklar C, Donahue B, et al. Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy. *Cancer*. Aug 15 1997;80(4):798-804.
40. Corrias A, Einaudi S, Ricardi U, et al. Thyroid diseases in patients treated during pre-puberty for medulloblastoma with different radiotherapeutic protocols. *J Endocrinol Invest*. Jun 2001;24(6):387-392.
41. Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. *Cancer*. Feb 1 2003;97(3):663-673.
42. Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. *N Engl J Med*. Jan 14 1993;328(2):87-94.
43. Faraci M, Barra S, Cohen A, et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. *Int J Radiat Oncol Biol Phys*. Dec 1 2005;63(5):1568-1575.
44. Berger C, Le-Gallo B, Donadieu J, et al. Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. *Bone Marrow Transplant*. May 2005;35(10):991-995.
45. Lahteenmaki PM, Chakrabarti S, Cornish JM, Oakhill AH. Outcome of single fraction total body irradiation-conditioned stem cell transplantation in younger children with malignant disease--comparison with a busulphan-cyclophosphamide regimen. *Acta Oncol*. 2004;43(2):196-203.
46. Thomas O, Mahe M, Campion L, et al. Long-term complications of total body irradiation in adults. *Int J Radiat Oncol Biol Phys*. Jan 1 2001;49(1):125-131.
47. Leung W, Hudson M, Zhu Y, et al. Late effects in survivors of infant leukemia. *Leukemia*. Jul 2000;14(7):1185-1190.
48. Leung W, Hudson MM, Strickland DK, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. *J Clin Oncol*. Sep 15 2000;18(18):3273-3279.
49. Michel G, Socie G, Gebhard F, et al. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Societe Francaise de Greffe de Moelle. *J Clin Oncol*. Jun 1997;15(6):2238-2246.
50. Al-Fiar FZ, Colwill R, Lipton JH, Fyles G, Spaner D, Messner H. Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants. *Bone Marrow Transplant*. May 1997;19(10):1019-1022.

51. Kauppila M, Koskinen P, Irjala K, Remes K, Viikari J. Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults. *Bone Marrow Transplant.* Aug 1998;22(4):331-337.
52. Hata M, Ogino I, Aida N, et al. Prophylactic cranial irradiation of acute lymphoblastic leukemia in childhood: outcomes of late effects on pituitary function and growth in long-term survivors. *Int J Cancer.* 2001;96 Suppl:117-124.
53. Mohn A, Chiarelli F, Di Marzio A, Impicciatore P, Marsico S, Angrilli F. Thyroid function in children treated for acute lymphoblastic leukemia. *J Endocrinol Invest.* Apr 1997;20(4):215-219.
54. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. *Bmj.* Oct 2 1993;307(6908):828-832.
55. de Klerk JM, van Isselt JW, van Dijk A, et al. Iodine-131 therapy in sporadic nontoxic goiter. *J Nucl Med.* Mar 1997;38(3):372-376.
56. Le Moli R, Wesche MF, Tiel-Van Buul MM, Wiersinga WM. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. *Clin Endocrinol (Oxf).* Jun 1999;50(6):783-789.
57. Nygaard B, Knudsen JH, Hegedus L, Scient AV, Hansen JE. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. *J Clin Endocrinol Metab.* Sep 1997;82(9):2926-2930.
58. Huysmans AK, Hermus RM, Edelbroek MA, et al. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. *Thyroid.* Aug 1997;7(4):535-539.
59. van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. *Cancer.* Apr 1 2002;94(7):2081-2089.
60. Brans B, Monsieurs M, Laureys G, Kaufman JM, Thierens H, Dierckx RA. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking. *Med Pediatr Oncol.* Jan 2002;38(1):41-46.
61. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. *Cancer.* Feb 15 2002;94(4 Suppl):1363-1372.
62. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20

- antibody and autologous stem-cell rescue. *J Clin Oncol*. Oct 1998;16(10):3270-3278.
63. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol*. Apr 15 2004;22(8):1469-1479.
64. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. *Blood*. Aug 15 2000;96(4):1259-1266.
65. Chen S, Li B, Xie H, et al. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma. *Cancer Biother Radiopharm*. Oct 2004;19(5):589-600.
66. Laverdiere C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. *Pediatr Blood Cancer*. Sep 2005;45(3):324-332.
67. Lin CM, Mao IF. Potential adverse health effects of low-level ionizing radiation exposure in a hospital setting. *Arch Environ Health*. Jul 2004;59(7):342-347.
68. Trerotoli P, Ciampolillo A, Marinelli G, Giorgino R, Serio G. Prevalence of thyroid nodules in an occupationally radiation exposed group: a cross sectional study in an area with mild iodine deficiency. *BMC Public Health*. 2005;5:73.
69. Volzke H, Werner A, Wallaschofski H, et al. Occupational exposure to ionizing radiation is associated with autoimmune thyroid disease. *J Clin Endocrinol Metab*. Aug 2005;90(8):4587-4592.
70. Kindler S, Roser M, Below H, et al. Thyroid disorders in employees of a nuclear power plant. *Thyroid*. Oct 2006;16(10):1009-1017.
71. Sugeno A, Asanuma K, Hama Y, et al. Thyroid abnormalities among children in the contaminated area related to the Chernobyl accident. *Thyroid*. Feb 1995;5(1):29-33.
72. Ito M, Yamashita S, Ashizawa K, et al. Childhood thyroid diseases around Chernobyl evaluated by ultrasound examination and fine needle aspiration cytology. *Thyroid*. Oct 1995;5(5):365-368.
73. Mangano JJ. Chernobyl and hypothyroidism. *Lancet*. May 25 1996;347(9013):1482-1483.
74. Williams D. Chernobyl and hypothyroidism. *Lancet*. Aug 17 1996;348(9025):476-477.
75. Kasatkina EP, Shilin DE, Rosenbloom AL, et al. Effects of low level radiation from the Chernobyl accident in a population with iodine deficiency. *Eur J Pediatr*. Dec 1997;156(12):916-920.
76. Vykhanets EV, Chernyshov VP, Slukvin, II, et al. 131I dose-dependent thyroid autoimmune disorders in children living around Chernobyl. *Clin Immunol Immunopathol*. Sep 1997;84(3):251-259.

77. Lomat L, Galburt G, Quastel MR, Polyakov S, Okeanov A, Rozin S. Incidence of childhood disease in Belarus associated with the Chernobyl accident. *Environ Health Perspect.* Dec 1997;105 Suppl 6:1529-1532.
78. Quastel MR, Goldsmith JR, Mirkin L, et al. Thyroid-stimulating hormone levels in children from Chernobyl. *Environ Health Perspect.* Dec 1997;105 Suppl 6:1497-1498.
79. Pacini F, Vorontsova T, Molinaro E, et al. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. *Lancet.* Sep 5 1998;352(9130):763-766.
80. Goldsmith JR, Grossman CM, Morton WE, et al. Juvenile hypothyroidism among two populations exposed to radioiodine. *Environ Health Perspect.* Apr 1999;107(4):303-308.
81. Vermiglio F, Castagna MG, Volnova E, et al. Post-Chernobyl increased prevalence of humoral thyroid autoimmunity in children and adolescents from a moderately iodine-deficient area in Russia. *Thyroid.* Aug 1999;9(8):781-786.
82. DeVita R, Olivieri A, Spinelli A, et al. Health status and internal radiocontamination assessment in children exposed to the fallout of the Chernobyl accident. *Arch Environ Health.* May-Jun 2000;55(3):181-186.
83. Emral R, Bastemir M, Gullu S, Erdogan G. Thyroid consequences of the Chernobyl nuclear power station accident on the Turkish population. *Eur J Endocrinol.* May 2003;148(5):497-503.
84. Ivanov VK, Chekin SY, Parshin VS, et al. Non-cancer thyroid diseases among children in the Kaluga and Bryansk regions of the Russian Federation exposed to radiation following the Chernobyl accident. *Health Phys.* Jan 2005;88(1):16-22.
85. Tronko MD, Brenner AV, Olijnyk VA, et al. Autoimmune thyroiditis and exposure to iodine 131 in the Ukrainian cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident: results from the first screening cycle (1998-2000). *J Clin Endocrinol Metab.* Nov 2006;91(11):4344-4351.
86. Cronkite EP, Bond VP, Conard RA. Medical effects of exposure of human beings to fallout radiation from a thermonuclear explosion. *Stem Cells.* May 1995;13 Suppl 1:49-57.
87. Zhumadilov Z, Gusev BI, Takada J, et al. Thyroid abnormality trend over time in northeastern regions of Kazakstan, adjacent to the Semipalatinsk nuclear test site: a case review of pathological findings for 7271 patients. *J Radiat Res (Tokyo).* Mar 2000;41(1):35-44.
88. Mushkacheva G, Rabinovich E, Privalov V, et al. Thyroid abnormalities associated with protracted childhood exposure to ¹³¹I from atmospheric emissions from the Mayak weapons facility in Russia.

- Radiat Res.* Nov 2006;166(5):715-722.
89. Kerber RA, Till JE, Simon SL, et al. A cohort study of thyroid disease in relation to fallout from nuclear weapons testing. *Jama.* Nov 3 1993;270(17):2076-2082.
90. Lyon JL, Alder SC, Stone MB, et al. Thyroid disease associated with exposure to the Nevada nuclear weapons test site radiation: a reevaluation based on corrected dosimetry and examination data. *Epidemiology.* Nov 2006;17(6):604-614.
91. Lloyd RD, Tripp DA, Kerber RA. Limits of fetal thyroid risk from radioiodine exposure. *Health Phys.* Apr 1996;70(4):559-562.
92. Davis S, Kopecky KJ, Hamilton TE, Onstad L. Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. *Jama.* Dec 1 2004;292(21):2600-2613.
93. Nedveckaite T, Motiejunas S, Kucinskas V, et al. Environmental releases of radioactivity and the incidence of thyroid disease at the Ignalina Nuclear Power Plant. *Health Phys.* Dec 2000;79(6):666-674.
94. Chang TC, Chen WL, Chang WP, Chen CJ. Effect of prolonged radiation exposure on the thyroid gland of residents living in 60Co-contaminated rebar buildings. *Int J Radiat Biol.* Nov 2001;77(11):1117-1122.
95. Yoshimoto Y, Ezaki H, Etoh R, Hiraoka T, Akiba S. Prevalence rate of thyroid diseases among autopsy cases of the atomic bomb survivors in Hiroshima, 1951-1985. *Radiat Res.* Mar 1995;141(3):278-286.
96. Nagataki S, Shibata Y, Inoue S, Yokoyama N, Izumi M, Shimaoka K. Thyroid diseases among atomic bomb survivors in Nagasaki. *Jama.* Aug 3 1994;272(5):364-370.
97. Fujiwara S, Carter RL, Akiyama M, et al. Autoantibodies and immunoglobulins among atomic bomb survivors. *Radiat Res.* Jan 1994;137(1):89-95.
98. Imaizumi M, Usa T, Tominaga T, et al. Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. *Jama.* Mar 1 2006;295(9):1011-1022.